Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor growth. The technique worked even when only a fraction of tumor cells were edited, making it practical for real-world treatment. Since NRF2 fuels resistance in several cancers, the approach could have broad impact.